Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paracetamol + chlorphenamine maleate is an over-the-counter (OTC) combination drug product developed by Abiogen. It combines paracetamol, a non-opioid analgesic and antipyretic, with chlorphenamine maleate, a first-generation alkylamine antihistamine. Paracetamol exerts its effects primarily through the inhibition of cyclooxygenase enzymes (COX-1 and COX-2) in the central nervous system, reducing prostaglandin synthesis to alleviate pain and fever. Chlorphenamine maleate acts as a competitive antagonist at the H1 histamine receptor, effectively reducing symptoms of allergic reactions and the common cold, such as sneezing, watery eyes, and runny nose. This combination is indicated for the symptomatic relief of pain and nasal congestion associated with the common cold and flu.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + chlorphenamine maleate.